Medizone's AsepticSure sterilization technology effective against adenovirus, MERS coronavirus
Medizone announced the midpoint results from the AsepticSure initiative, which was developed in collaboration with a team of world-renowned virologists.
"By destroying both of these viruses, one a non-enveloped virus and the second an enveloped coronavirus, our understanding of the biological limits for AsepticSure has been expanded dramatically and of course so has the range of medical applications," Medizone President Michael Shannon said.
Shannon said Medizone was still testing the technology with the coronavirus but plans to move on to the norovirus after the work is complete.
"These new findings should have intriguing implications for the management of new deadly outbreaks worldwide," Shannon said. "Experts in this field have known for years that bacterial spores and non-enveloped viruses are at the top of the biological resistance list for pathogens, and we have data by the truckload confirming that AsepticSure can achieve 100 percent kill of these pathogens at very high concentrations. What is most exciting about these recent findings is that highly lethal viruses such as Ebola should be extremely susceptible to AsepticSure disinfection, which may therefore see AsepticSure emerge as a vital component in global efforts to control these new deadly outbreaks."